SYSTEMATIC REVIEW article
Front. Med.
Sec. Ophthalmology
This article is part of the Research TopicEarly-stage retinal diseases: Pathophysiology, Diagnostics and TherapeuticsView all 5 articles
Impact of Anti-VEGF Therapy on Choroidal Thickness in Patients with Retinal Vein Occlusion: A Systematic Review and Meta-Analysis
Provisionally accepted
- Second Affiliated Hospital of Soochow University, Suzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To systematically review and analyze existing literature reporting changes in choroidal thickness at 1, 3, 6, and 12 months following anti-VEGF treatment in patients with retinal vein occlusion (RVO). Methods: A comprehensive literature search identified 16 eligible studies including a total of 545 patients and 547 eyes. Data were extracted on subfoveal choroidal thickness at baseline and at specified follow-up intervals. Meta-analyses were performed to assess pooled changes in choroidal thickness after treatment, and subgroup analyses were conducted based on anti-VEGF drug type and treatment regimen. Results: At 1-and 3-month follow-up, anti-VEGF therapy was associated with a significant reduction in choroidal thickness. By 12 months, choroidal thickness tended to return toward baseline levels, suggesting potential stabilization or structural adaptation. Subgroup analyses indicated that the effects on choroidal thickness may vary among different anti-VEGF agents, with ranibizumab and aflibercept showing significant early reductions, while bevacizumab demonstrated more delayed effects. Further subgroup analyses based on RVO type showed that at one month, choroidal thickness was significantly reduced in branch retinal vein occlusion patients, but not in central retinal vein occlusion patients, suggesting potential differences in drug response between RVO subtypes. However, given the limited number of studies within some subgroups, these findings should be interpreted with caution. Conclusion: In patients with RVO, anti-VEGF therapy appears to induce an early reduction in choroidal thickness, which tends to return toward baseline with longer follow-up. Subgroup analyses provided preliminary insights into the potential influence of different agents, disease subtypes, and treatment regimens. However, this study was limited by the small number of eligible studies and the heterogeneity of study designs. Therefore, the findings should be regarded as exploratory and interpreted with caution. Future prospective studies with larger sample sizes, standardized imaging protocols, and longer follow-up are needed to clarify the clinical relevance of choroidal thickness changes in RVO patients undergoing anti-VEGF therapy.
Keywords: Retinal Vein Occlusion, Optical Coherence Tomography, Choroid, Choroidalthickness, anti vascular endothelial growth factor, bevacizumab, Aflibercept, Ranibizumab
Received: 10 Jul 2025; Accepted: 24 Nov 2025.
Copyright: © 2025 Cheng, Zeng, Liu, Liu, Liu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yulong Liu, yulongliu2002@126.com
Guoxu Xu, xuxuxuguo@yeah.net
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.